Merck Profit Beats Analysts Estimates
Submitted by Amit Pathania on Tue, 02/16/2010 - 17:51
After the completion of company purchase of rival Schering-Plough Corp., the second largest U. S. drug maker Merck & Co. claimed its fourth-quarter profit mounted for revenue to beat analyst estimates by 1 cent.
Schering drug won narrow support from US panel
Submitted by Jason Ramsey on Tue, 10/06/2009 - 09:19
Schering-Plough Corp won a narrow vote from the Food and drug Administration (FDA) advisory panel recently to market its drug PegIntron, available in injection form, for melanoma patients undergoing surgery for skin cancer.
Latest News
|
|
|
|
|
|
|
|
|
|
|
|
